Seeking Alpha
 

Portola Pharmaceuticals (PTLA)

- NASDAQ
  • Thu, Feb. 5, 5:35 PM
    • Top gainers, as of 5:15 p.m.: PTLA +16.4%. GSB +15.6%. TWTR +11.4%. UBNT +10.8%. YRCW +8.3%.
    • Top losers, as of 5:15 p.m.: P -21.0%. FWM -15.0%. MXWL -14.6%. NTGR -13.5%. CTRL -10.4%.
    | Comment!
  • Fri, Jan. 9, 9:10 AM
    | 4 Comments
  • Oct. 1, 2014, 12:46 PM
    | Comment!
  • Oct. 1, 2014, 12:10 PM
    • Thinly-traded Portola Pharmaceuticals (PTLA +15.5%) jumps on a 2x surge in volume albeit on turnover of less than 600K shares in response to its announcement of positive results from a Phase 3 clinical trial evaluating the safety and efficacy of andexanet alfa as an antidote to a Factor Xa inhibitor.
    • Top-line efficacy data demonstrated that an IV bolus of andexanet alfa immediately and significantly reduced the anticoagulation activity of Bristol-Myers Squibb (BMY -1.4%) and Pfizer's (PFE -1.3%) direct Factor Xa inhibitor Eliquis (apixaban). The results were highly statistically significant.
    • CEO William Lis says, "Andexanet alfa represents a potential important advance to the field of anticoagulation for Factor Xa inhibitor patients who suffer a major bleeding episode or those requiring emergency surgery."
    • The company expects to file a BLA with the FDA for the Breakthrough Therapy-designated product candidate by the end of 2015.
    | 2 Comments
  • Oct. 16, 2013, 10:58 AM
    • Portola Pharmaceuticals (PTLA -7.1%) falls sharply after announcing a $100M public offering.
    • The deal will reportedly include shares from selling stockholders.
    • The company intends to use a portion of the proceeds to "support the pursuit of an accelerated approval process for Andexanet alfa." (PR)
    | Comment!
  • Oct. 9, 2013, 8:26 AM
    | Comment!
  • Jun. 27, 2013, 3:06 PM
    Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered into a clinical collaboration agreement with Daiichi Sankyo (DSNKY.PK) to conduct a Phase 2 study of its investigational Factor Xa inhibitor antidote PRT4445, or andexanet alfa. The study will at several different doses to reverse the anticoagulant effects of Daiichi Sankyo's edoxaban in healthy volunteers.
    | Comment!
  • Jun. 27, 2013, 2:44 PM
    Portola Pharmaceuticals (PTLA +10.1%) moves up after saying late yesterday that it had entered into a clinical collaboration agreement with Daiichi Sankyo (DSNKY.PK) to conduct a Phase 2 study of its investigational Factor Xa inhibitor antidote PRT4445, or andexanet alfa. The study will at several different doses to reverse the anticoagulant effects of Daiichi Sankyo's oral direct Factor Xa inhibitor edoxaban in healthy volunteers.
    | Comment!
Visit Seeking Alpha's
PTLA vs. ETF Alternatives
Company Description
Portola Pharmaceuticals Inc is a biopharmaceutical company. It develops & commercializes novel therapeutics in the areas of thrombosis, other hematologic disorders & inflammation for patients who currently have limited or no approved treatment options.